CN108548926B - A kind of creatine kinase isozyme detection kit - Google Patents
A kind of creatine kinase isozyme detection kit Download PDFInfo
- Publication number
- CN108548926B CN108548926B CN201810239106.5A CN201810239106A CN108548926B CN 108548926 B CN108548926 B CN 108548926B CN 201810239106 A CN201810239106 A CN 201810239106A CN 108548926 B CN108548926 B CN 108548926B
- Authority
- CN
- China
- Prior art keywords
- reagent
- creatine kinase
- kit
- kinase isozyme
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/50—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving creatine phosphokinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9123—Phosphotransferases in general with a nitrogenous group as acceptor (2.7.3), e.g. histidine kinases
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
This application involves a kind of creatine kinase isozyme detection kits.The kit includes the first reagent, the second reagent.First reagent includes buffer, preservative, increases solidifying agent, surfactant, protective agent, blocking agent；Second reagent includes buffer, stabilizer, preservative, protective agent, polystyrene latex particles, creatine kinase isozyme antibody.The kit of the application has many advantages, such as that stability is good, high specificity, can be applied to biochemical instruments and carries out large batch of measurement, can substitute chemiluminescence product, reduces hospital's cost of determination.
Description
Technical field
The application belongs to external diagnosis reagent field, and in particular to detection of the immunoturbidimetry to creatine kinase isozyme.
Background technique
Nineteen sixty CK is studied first and thinks to be used to diagnose ACS, but since its specificity is relatively worse than 1970
Replaced afterwards by creatine kinase isozyme (CKMB).Therewith, CKMB since it has, preferably specific and be proposed as by sensitivity
The diagnosis goldstandard of previous generation myocardial infarction (AMI).
However, the CKMB in children's skeletal muscle can be higher since there is also a small amount of CKMB in skeletal muscle.Therefore, specifically
Property is bad, there is the risk for causing mistaken diagnosis.Currently, replaced new goldstandard marker cTnI.
Nevertheless, CKMB still has important clinical meaning in ACS and AMI diagnosis.Firstly, when myocardial damage is drawn
After sending out episode, the time ratio cTnI that CKMB occurs in blood is early, therefore can be used as the marker of early diagnosis.Its
Secondary, CKMB is the preferred marker of thromboembolism treatment recruitment evaluation, when the myocardium coronary arteries of obstruction are led to again, in cardiac muscle cell
CKMB can be rushed out by blood flow, and CKMB is caused to increase, and can be assessed according to the situation of change of CKMB concentration using this feature molten
Bolt therapeutic effect.Again, CKMB detection can be used to assess myocardial infarct size and again infarct.Finally, when cTnI it is unavailable or
When the result of person cTnI is difficult to make a definite diagnosis, CKMB is the effective auxiliary sign object of cTnI.
Currently, the measurement of conventional CK-MB is mainly using immunodepression, what it was measured is the vigor of CK-MB.
CK-BB is very little in the intracorporal content of normal person, therefore the method ignores the presence of CK-BB, it is assumed that in serum only have CK-MM and
CK-MB.The polyclonal antibody of anti-CK-M subunit is added in reagent, thus inhibit M subunit active in CK-MM and CK-MB,
It measures result and is equivalent to B subunit active in CK-MB, by result multiplied by 2 that is, CK-MB vigor.The method is rapid, simple
It is clean, time saving, have higher sensibility, but influence factor and defect are numerous.
Enzyme-linked immunization (ELISA) is based on CK-MB present in double-antibody method detection serum.Cardinal principle will be that is, will
A wherein strain antibody for pairing monoclonal antibody is coated on 96 orifice plates, and serum sample to be checked is added, and is incubated for certain time, is washed away extra liquid
Body is added HRP enzyme target and accordingly corresponds to monoclonal antibody, develops the color under last TMB, and then determine CK-MB in sample according to absorbance
Concentration.The method high specificity, but need manually to be operated, and detection time is longer.
Colloid gold immune turbidimetry, such as CN103926405A provide a kind of creatine kinase isozyme detection kit,
It includes the first reagents and the second reagent, wherein the first reagent includes: 0.2%BSA, 0.05%Tween20,50mM phosphate are slow
Fliud flushing pH7.2,0.2%PEG20000,0.1%NaN3；Second reagent includes: 1%BSA, 50nm-100nm gold particle, 10mmol
Phosphate buffer pH7.2,0.1%NaN3, 20% sucrose, 5% glycerol.
Electrochemical luminescence (ECL) is a kind of specific chemical luminescence-producing reaction caused in electrode surface by electrochemistry, the method
The advantages of be high specificity, precision is excellent, the disadvantage is that expensive, and is monopolized substantially by external IVD giant.
Rheumatoid factor existing for patient's body (RF) can interfere many immunological detection methods.IgM type RF and IgG type RF
In conjunction with the Fc of capture antibody and label secondary antibody in detection reagent, cause to detect false positive results.RF is to different detection methods
Annoyance level it is different, influence degree is not directly proportional to RF concentration.Currently, the detection reagent used in clinic does not have mostly
Take well prevent RF interfere measure (progress that rheumatoid factor interferes immunoassays, Medical review 2015
Vol 21,19:3495).Currently, the strategy for preventing RF from interfering includes: the sample to be tested solid phase adsorption for being connected with thermal denaturation IgG
Agent is pre-processed (Euroimmune company), is detected again after 4 DEG C of centrifugations overnight；When detecting antigen, 2 mercapto ethanol can be used
It is added in Sample dilution or sample, IgM type RF is made to degrade.
In view of above-mentioned, that there is still a need for a species specificity for this field is high, false positive is low, anti-RF interference and cheap CKMB
Detection kit.
Summary of the invention
According to some embodiments, a kind of creatine kinase isozyme Immunoturbidimetry detection reagent is provided
Box, it includes the first reagent and the second reagent,
Wherein, first reagent includes:
Second reagent includes:
In some embodiments, the buffer is selected from: glycine buffer, TRIS-HCl buffer, HEPES buffering
Liquid.
In some embodiments, the preservative is selected from: Sodium azide, thimerosal, ProClin300.
In some embodiments, polyethylene glycol is selected from: PEG6000, PEG8000, PEG12000, PEG20000, preferably
PEG20000。
In some embodiments, the surfactant is selected from: Tween 20, Tween 80, NP40, thesit.
In some embodiments, the surfactant is Tween 80.
In some embodiments, the protective agent is selected from: bovine serum albumin, ovalbumin, skimmed milk, calf serum.
In some embodiments, the blocking agent is sheep anti-mouse igg.Specific theory is not limited to, existing for patient's body
Rheumatoid factor RF can interfere many immunological detection methods, IgM type RF and IgG type RF and capture antibody in detection reagent and
It marks the Fc of secondary antibody to combine, causes to detect false positive results.Inventors have surprisingly discovered that sheep anti-mouse igg (is not limited to resist
The particular sequence of body) RF existing for patient's body can be effectively shielded, improve the appearance of false positive results.
In some embodiments, the stabilizer is selected from: sucrose, glycerol, trehalose, glucose.
In some embodiments, the stabilizer is sucrose.
In some embodiments, the surface functional group of the polystyrene latex particles is selected from: amino, carboxyl, chloromethane
Base, epoxy group, preferably carboxyl.
In some embodiments, the average grain diameter of the polystyrene latex particles is 200nm to 500nm, preferably
300nm.Technical staff is appreciated that for example, the partial size of polystyrene latex particles is 300nm, it is not intended to exist in reagent
The partial size of each latex particle be strictly 300nm.In fact, in the preparation process of commercially obtainable latex particle
In, the partial size that cannot achieve each latex particle is completely the same, and the latex particle of model 300nm refers in latex particle
Group in latex particle partial size with normal state formal distribution near 300nm (such as, but not limited to, in ± 20% range).Cause
This, partial size can be understood as the average grain diameter of latex particle.
In some embodiments, the creatine kinase isozyme antibody is originated from mouse or sheep.
In some embodiments, the creatine kinase isozyme antibody is monoclonal antibody.
According to some embodiments, a kind of creatine kinase isozyme Immunoturbidimetry detection reagent is provided
Box, it includes the first reagent and the second reagent,
Wherein, first reagent includes:
Second reagent includes:
The antibody is source of mouse monoclonal antibody；
The average grain diameter of the latex particle is 300nm；
The latex particle is carboxyl modified；
The blocking agent is sheep anti-mouse igg.
According to some embodiments, a kind of creatine kinase isozyme Immunoturbidimetry detection reagent is provided
Box, it includes the first reagent and the second reagent,
Wherein, first reagent includes:
Second reagent includes:
The antibody is source of mouse monoclonal antibody；
The average grain diameter of the latex particle is 300nm；
The latex particle is carboxyl modified；
The blocking agent is sheep anti-mouse igg.
According to some embodiments, a kind of creatine kinase isozyme Immunoturbidimetry detection reagent is provided
Box, it includes the first reagent and the second reagent,
Wherein, first reagent includes:
Second reagent includes:
The antibody is source of mouse monoclonal antibody；
The average grain diameter of the latex particle is 300nm；
The latex particle is carboxyl modified；
The blocking agent is sheep anti-mouse igg.
According to some embodiments, providing blocking agent is improving the purposes in testing result false positive.
In some embodiments, the blocking agent is sheep anti-mouse igg.In some embodiments, the detection refers to
The detection of creatine kinase isozyme Immunoturbidimetry.
According to some embodiments, the purposes of blocking agent RF interference in improving detection is provided.In some embodiments
In, the blocking agent is sheep anti-mouse igg.In some embodiments, the detection is that the enhancing of creatine kinase isozyme latex is exempted from
The detection of epidemic disease turbidimetry.
In some embodiments, by based on v/v 0.1% to the 2% introducing blocking agent into detection reagent, to change
RF interference and improvement testing result false positive in kind detection.
Detailed description of the invention
Fig. 1 shows the calibration curve of the application kit.
Specific embodiment
The preparation of 1. first reagent of embodiment
1. weigh 17.87g HEPES, 13.15g NaCl, 9g PEG20000,15g Tween 80,1.5g Sodium azide,
7.5g BSA, 15mL blocking agent (5mg/ml), are dissolved in 1.0L distilled water, adjust ph to 7.2, are settled to 1.5L up to reagent the
One reagent (1):
2. alternatively, weigh 9.09g Tris, 13.15g NaCl, 9g PEG20000,15g Tween80,1.5g Sodium azide,
7.5g BSA, 10mL blocking agent (ibid), are dissolved in 1.0L distilled water, adjust ph to 7.2, are settled to 1.5L and prepare the first reagent
(2):
3. alternatively, weighing 5.63g glycine, 13.15g NaCl, 9g PEG20000,15g Tween 80,1.5g nitrine
Sodium, 7.5g BSA, 10mL blocking agent (ibid), are dissolved in 1.0L distilled water, adjust ph to 7.2, are settled to 1.5L preparation first
Reagent (3):
The preparation of 2. antibody of embodiment coating particle
1. particle (300nm, carboxyl) is diluted to 1% (w/v) with HEPES buffer solution；
2. antibody (mouse monoclonal) is diluted to 0.5mg/ml with HEPES buffer solution；
3. the EDAC aqueous solution that concentration is 0.1% to 1% (w/v) is added into the particle of step 1, in constant-temperature table
37 DEG C of reaction 30min；
4. the antibody of step 2,37 DEG C of reaction 3h in constant-temperature table after reaction, is added；
5. adding sealer, ambient temperature overnight is placed；
6. overnight particle will be closed, it is added cleaning solution cleaning centrifugation 3 times, saves, it is spare.
Step 1 and step 2 sequence are interchangeable.
The preparation of 3. second reagent of embodiment
1. 400mL distilled water is added in particle prepared by embodiment 2, it is folded to add 18.76g glycine, 2.5g BSA, 0.5g
Nitrogen sodium, 50g sucrose, stir and evenly mix, and adjust ph to 7.5, add distilled water to 500mL, ultrasound to dominant wavelength absorbance substantially not
Change up to the second reagent (1):
2. alternatively, 400mL distilled water is added in particle prepared by embodiment 2, add 5.96g HEPES, 2.5g BSA,
0.5g Sodium azide, 50g sucrose, stir and evenly mix, and adjust ph to 7.5, add distilled water to 500mL, ultrasound to dominant wavelength absorbance
Being basically unchanged is up to the second reagent (2):
3. alternatively, 400mL distilled water is added in particle prepared by embodiment 2, add 3.03g Tris, 2.5g BSA,
0.5g Sodium azide, 50g sucrose, stir and evenly mix, and adjust ph to 7.5, add distilled water to 500mL, ultrasound to dominant wavelength absorbance
Being basically unchanged is up to the second reagent (3):
The preparation of 4. kit of embodiment
Aforementioned agents are assembled into kit according to following table.
The assembling of 1. kit of table
| First reagent | Second reagent | |
| Kit 1 | First reagent (1) | Second reagent (1) |
| Kit 2 | First reagent (2) | Second reagent (1) |
| Kit 3 | First reagent (3) | Second reagent (1) |
| Kit 4 | First reagent (2) | Second reagent (2) |
| Kit 5 | First reagent (3) | Second reagent (2) |
| Kit 6 | First reagent (3) | Second reagent (3) |
Test case
1. sensitivity test of test case
6 kits prepared by above-described embodiment are tested using full automatic biochemical apparatus (for example, Hitachi 7180).
Measurement wavelength be 660nm, sample sampling amount be 10 μ L, be added 150 μ L the first reagent, 37 DEG C of constant temperature 5min, so
The second reagent of 50 μ L is added afterwards, reads absorbance A 2 after 1,37 DEG C of absorbance A of reading, 4 points of incubation 18 seconds after 42 seconds, reaction is inhaled
Luminosity is Δ A=A2-A1；Performance verification is carried out to 6 above-mentioned embodiments, result is as follows:
The detection limit result of table 2.
According to measurement as above, it is known that kit 1 to 6 realizes good sensitivity, and wherein kit 1 is optimal side
Case, sensitivity reach 1ng/ml.
The screening of 2. surfactant of test case
According to the preparation method of kit 1, following kit is prepared, difference, which is only that, divides surfactant Tween 80
Tween 20, NP40, thesit are not replaced with, and test the Anti-Jamming to triglycerides chaff interferent.
The screening of 3. surfactant of table
As can be seen that the anti-chyle ability of Tween-80 is most strong.
Influence of 3. blocking agent of test case to false positive results
Contrast agent box is prepared according to the preparation method of kit 1, difference is only that without blocking agent.It is each with preparation
Kit test contains or the sample without 500IU/ml RF.As a result as follows, display blocking agent can significantly improve test knot
The false positive of fruit, avoids RF from interfering.
Influence of 4. blocking agent of table to false positive results
Claims (2)
1. a kind of creatine kinase isozyme Immunoturbidimetry detection kit, it includes the first reagents and second to try
Agent,
Wherein, first reagent includes:
Second reagent includes:
The antibody is source of mouse monoclonal antibody；
The average grain diameter of the latex particle is 300nm；
The latex particle is carboxyl modified；
The blocking agent is sheep anti-mouse igg.
2. a kind of creatine kinase isozyme Immunoturbidimetry detection kit, it includes the first reagents and second to try
Agent,
Wherein, first reagent includes:
Second reagent includes:
The antibody is source of mouse monoclonal antibody；
The average grain diameter of the latex particle is 300nm；
The latex particle is carboxyl modified；
The blocking agent is sheep anti-mouse igg.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810239106.5A CN108548926B (en) | 2018-03-22 | 2018-03-22 | A kind of creatine kinase isozyme detection kit |
| PCT/CN2019/077813 WO2019179333A1 (en) | 2018-03-22 | 2019-03-12 | Creatine kinase isoenzyme assay kit |
| US16/982,664 US20210063397A1 (en) | 2018-03-22 | 2019-03-12 | Creatine kinase isoenzyme assay kit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810239106.5A CN108548926B (en) | 2018-03-22 | 2018-03-22 | A kind of creatine kinase isozyme detection kit |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108548926A CN108548926A (en) | 2018-09-18 |
| CN108548926B true CN108548926B (en) | 2019-11-08 |
Family
ID=63516974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810239106.5A Active CN108548926B (en) | 2018-03-22 | 2018-03-22 | A kind of creatine kinase isozyme detection kit |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20210063397A1 (en) |
| CN (1) | CN108548926B (en) |
| WO (1) | WO2019179333A1 (en) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108548926B (en) * | 2018-03-22 | 2019-11-08 | 北京九强生物技术股份有限公司 | A kind of creatine kinase isozyme detection kit |
| CN111721935A (en) * | 2019-03-29 | 2020-09-29 | 北京九强生物技术股份有限公司 | Sugar chain antigen CA153 detection kit |
| CN110736839A (en) * | 2019-09-17 | 2020-01-31 | 北京九强生物技术股份有限公司 | Latex-enhanced immunoturbidimetric assay kit for cytokeratin 19 fragments |
| CN110716038B (en) * | 2019-10-23 | 2022-08-30 | 俞梦越 | Acute coronary syndrome complement detection kit and use method thereof |
| CN112858678B (en) * | 2019-11-12 | 2023-10-27 | 上海奥普生物医药股份有限公司 | Creatine kinase isoenzyme detection kit, preparation method and application |
| CN111041065A (en) * | 2019-12-31 | 2020-04-21 | 扬中酵诚生物技术研究有限公司 | CK kit and manufacturing process thereof |
| CN113125700B (en) * | 2019-12-31 | 2023-08-08 | 科美博阳诊断技术(上海)有限公司 | Homogeneous detection kit for creatine kinase isozymes and application thereof |
| CN113125721B (en) * | 2019-12-31 | 2023-07-07 | 科美博阳诊断技术(上海)有限公司 | Homogeneous detection kit for creatine kinase isozymes and application thereof |
| CN111057746B (en) * | 2020-01-03 | 2023-10-27 | 浙江夸克生物科技有限公司 | Creatine kinase isoenzyme determination kit |
| WO2021147453A1 (en) | 2020-01-20 | 2021-07-29 | 北京九强生物技术股份有限公司 | Quantitative kit for myxovirus resistance protein 1 |
| CN112098647A (en) * | 2020-02-28 | 2020-12-18 | 安徽大千生物工程有限公司 | Kit for determining CK-MB based on latex enhanced immunoturbidimetry and preparation and use methods thereof |
| CN111562372B (en) * | 2020-05-15 | 2022-04-15 | 深圳上泰生物工程有限公司 | Latex enhanced immunoturbidimetry kit for detecting creatine kinase isoenzyme CK-MB |
| CN112540177A (en) * | 2020-11-30 | 2021-03-23 | 美康生物科技股份有限公司 | High-sensitivity creatine kinase isoenzyme detection kit and preparation method thereof |
| CN113030470B (en) * | 2021-02-24 | 2022-03-18 | 江西英大生物技术有限公司 | Creatine kinase isoenzyme determination kit |
| CN114150040A (en) * | 2021-11-12 | 2022-03-08 | 中生北控生物科技股份有限公司 | Crystallization-resistant creatine kinase detection kit and preparation method thereof |
| CN114252597A (en) * | 2021-12-08 | 2022-03-29 | 南京诺唯赞医疗科技有限公司 | Sample pad sealing agent and preparation method and application thereof |
| CN114487420A (en) * | 2022-01-14 | 2022-05-13 | 广西康柏莱科技有限公司 | Creatine kinase isoenzyme detection kit |
| CN115236323A (en) * | 2022-06-17 | 2022-10-25 | 北京安百胜诊断科技有限公司 | Kit for detecting rabies antibody in human plasma by latex enhanced immunoturbidimetry |
| CN115261354B (en) * | 2022-07-27 | 2023-12-15 | 东方伊诺(苏州)医疗科技有限公司 | Creatine kinase isoenzyme quality control product, preparation method thereof and detection kit |
| CN115927245A (en) * | 2022-11-14 | 2023-04-07 | 浙江爱康生物科技有限公司 | Preparation method of creatine kinase isoenzyme and determination kit thereof |
| CN116008567A (en) * | 2023-01-04 | 2023-04-25 | 北京九强生物技术股份有限公司 | Gastrin 17 detection kit |
| CN116593701B (en) * | 2023-07-19 | 2024-01-23 | 北京豪迈生物工程股份有限公司 | Creatine kinase isoenzyme detection kit containing biological blocker |
| CN116891529B (en) * | 2023-08-28 | 2023-12-22 | 安徽千诚生物技术有限公司 | Creatine kinase isozyme antibody and CKBB detection kit |
| CN117491646A (en) * | 2023-11-13 | 2024-02-02 | 深圳上泰生物工程有限公司 | Detection kit for heart-type fatty acid binding protein and application thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54119291A (en) * | 1978-01-16 | 1979-09-17 | Smith Kline Instr | Method for detecting and measuring creatine kinase isoenzyme |
| US4267271A (en) * | 1977-10-27 | 1981-05-12 | Washington University | Radioimmunoassay for isoenzymes of creative kinase having a B-subunit and reagents therefor |
| EP1536236A1 (en) * | 2003-11-28 | 2005-06-01 | Sysmex Corporation | Reagent for measuring clotting time and method for measuring clotting time |
| CN103048464A (en) * | 2012-10-17 | 2013-04-17 | 武汉生之源生物科技有限公司 | Neutrophile granulocyte gelatinase related lipid transport protein detection kit and preparation method thereof |
| CN105334318A (en) * | 2015-11-28 | 2016-02-17 | 宁波美康生物科技股份有限公司 | Portable C reaction protein detection kit |
| CN106645681A (en) * | 2016-10-31 | 2017-05-10 | 广州科方生物技术股份有限公司 | Blocking agent kit for immunochromatography determination and using method thereof |
| CN106814193A (en) * | 2016-12-23 | 2017-06-09 | 美康生物科技股份有限公司 | Neutrophil gelatinase-associated lipocalin reagent box for detecting content |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130309704A1 (en) * | 2011-01-26 | 2013-11-21 | Kowa Company, Ltd. | Method and apparatus for measuring physiologically active substance derived from organism |
| JP2013125005A (en) * | 2011-12-16 | 2013-06-24 | Mitsubishi Chemical Medience Corp | Latex agglutination immunoreagent for ck-mb measurement and measuring method |
| ES2708781T3 (en) * | 2014-04-30 | 2019-04-11 | Fujifilm Wako Pure Chemical Corp | Method to test the isozyme MB of creatine kinase and kit to be used in the same |
| CN103926405B (en) * | 2014-05-08 | 2016-02-24 | 北京玖佳宜科技有限公司 | Creatine kinase isozyme detection kit and preparation thereof |
| CN108548926B (en) * | 2018-03-22 | 2019-11-08 | 北京九强生物技术股份有限公司 | A kind of creatine kinase isozyme detection kit |
-
2018
- 2018-03-22 CN CN201810239106.5A patent/CN108548926B/en active Active
-
2019
- 2019-03-12 WO PCT/CN2019/077813 patent/WO2019179333A1/en active Application Filing
- 2019-03-12 US US16/982,664 patent/US20210063397A1/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4267271A (en) * | 1977-10-27 | 1981-05-12 | Washington University | Radioimmunoassay for isoenzymes of creative kinase having a B-subunit and reagents therefor |
| JPS54119291A (en) * | 1978-01-16 | 1979-09-17 | Smith Kline Instr | Method for detecting and measuring creatine kinase isoenzyme |
| EP1536236A1 (en) * | 2003-11-28 | 2005-06-01 | Sysmex Corporation | Reagent for measuring clotting time and method for measuring clotting time |
| CN103048464A (en) * | 2012-10-17 | 2013-04-17 | 武汉生之源生物科技有限公司 | Neutrophile granulocyte gelatinase related lipid transport protein detection kit and preparation method thereof |
| CN105334318A (en) * | 2015-11-28 | 2016-02-17 | 宁波美康生物科技股份有限公司 | Portable C reaction protein detection kit |
| CN106645681A (en) * | 2016-10-31 | 2017-05-10 | 广州科方生物技术股份有限公司 | Blocking agent kit for immunochromatography determination and using method thereof |
| CN106814193A (en) * | 2016-12-23 | 2017-06-09 | 美康生物科技股份有限公司 | Neutrophil gelatinase-associated lipocalin reagent box for detecting content |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108548926A (en) | 2018-09-18 |
| WO2019179333A1 (en) | 2019-09-26 |
| US20210063397A1 (en) | 2021-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108548926B (en) | A kind of creatine kinase isozyme detection kit | |
| CN108535491B (en) | A kind of latex enhancing immune of Troponin I is than turbid detection kit | |
| CN104237522B (en) | Adiponectin reagent box for detecting content and preparation method thereof | |
| CN107942069A (en) | A kind of NGAL latex immunoturbidimetries detection kit and preparation method thereof | |
| WO2018129885A1 (en) | Detection kit for whole blood c-reactive protein | |
| US20190049439A1 (en) | Kit for a Determination Method for Calprotectin and the Use of Calprotectin as a Predictive Marker for Cardiovascular Disease | |
| CN105988000B (en) | A kind of kit and method measuring glycocholic acid concentration | |
| CN105137089B (en) | Serum ferritin content detection kit | |
| CN107607708A (en) | Suppress the latex enhancing immune of rheumatoid factor interference than turbid reagent | |
| CN109633167A (en) | A kind of human serum amyloid A assay kit of highly sensitive, wide detection range | |
| BR112019023210A2 (en) | METHOD FOR DETERMINING MEMBERS OF THE S100 FAMILY OF CALCIUM-BINDING PROTEINS THROUGH IMMUNOTURBIDIMETRY | |
| CN106932589A (en) | Determine kit of human serum RBP ELISA content and preparation method thereof | |
| CN109613259A (en) | A kind of people's heparin-binding protein assay kit of highly sensitive, wide detection range | |
| CN105974106B (en) | 11- dehydrogenations-thromboxane B2 assay kit and application thereof | |
| CN109765382A (en) | A kind of latex enhancing immune of serum cardiac troponin T is than turbid detection kit | |
| CN109444427A (en) | A kind of kit detecting human parvovirus IgM antibody | |
| CN107957495A (en) | A kind of CK-MB detection kits and its application method | |
| CN109613276A (en) | A kind of anti-Miao Leguan hormone determination kit of people of highly sensitive, wide detection range | |
| CN111896748A (en) | Anti-streptolysin O determination kit | |
| CN105223365A (en) | GP73 latex enhancing immune turbidimetry Quantitative in vitro measures diagnostic kit | |
| CN109212188A (en) | A kind of gastrin-releasing peptide precursor detection kit convenient for clinical application | |
| CN102628866A (en) | Liquid double reagent kit for determining ferritin in serum by utilization of IGY ferritin antibody through latex enhanced turbidimetric immunoassay | |
| Hyytiä et al. | Skeletal troponin I cross-reactivity in different cardiac troponin I assay versions | |
| CN105759050B (en) | It is a kind of quantitatively to detect Troponin I content immunofluorescent reagent box and preparation method | |
| CN105891501A (en) | Colloidal gold immunocolorimetry kit for detecting retinol conjugated protein (RBP) and preparation method of kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |